• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ViaCyte closes $45M financing for stem cell-derived type 1 diabetes therapies

June 9, 2021 By Sean Whooley

ViaCyteViaCyte announced today that it closed a $45 million Series D financing tranche to bring the total round to more than $115 million.

San Diego-based ViaCyte said in a news release that proceeds raised in the financing will be earmarked for its advanced portfolio of cell-derived therapies designed to provide a functional cure for patients with type 1 diabetes.

Currently, the company is advancing a Phase II clinical study on the PEC-Encap product candidate, a treatment comprised of pancreatic islet precursor cells encapsulated in a novel membrane. ViaCyte developed PEC-Encap in partnership with W.L. Gore & Associates.

ViaCyte said it remains on track to provide data on its second Phase II product candidate, PEC-Direct, in the first half of 2022, with preliminary data set to be presented at the American Diabetes Association Scientific Sessions later this month.

The financing round received contributions from existing investors Bain Capital Life Sciences, TPG Capital, RA Capital Management and Sanderling Ventures, among other long-time insiders. New investors include Adage Capital Partners, Invus Group, Asymmetry Ventures and Artis Ventures.

“There have been few paradigm-shifting innovations in the 100 years since the discovery of insulin. ViaCyte’s portfolio of stem cell-derived therapies are first-in-category, first-in-class products that represent major advances in finding a functional cure for type 1 diabetes and other chronic diseases in the future,” ViaCyte president & CEO Michael Yang said in the release. “This financing should allow us to accelerate the development of our three novel approaches to reduce the burden faced by people with type 1 diabetes. With several of our therapies already in the clinic, we look forward to an exciting year of progress in our clinical trials.”

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Featured, Funding Roundup Tagged With: ViaCyte

IN CASE YOU MISSED IT

  • Study backs Fluidx embolic device for vessel filling
  • Senseonics stock is up as it sticks by revenue guidance
  • Rapid Dose closes first tranche of $5M financing
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS